Cefuroxime for Injection New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime for injection

viatris limited - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime  

Cefuroxime-AFT New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime-aft

aft pharmaceuticals ltd - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

Cefuroxime Sodium New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime sodium

hospira nz ltd - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime

Zinacef New Zealand - English - Medsafe (Medicines Safety Authority)

zinacef

glaxosmithkline nz limited - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;  ;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime     - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include - respiratory tract infections for example, acute exacerbation of chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septic ar

Cefuroxime Actavis New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime actavis

teva pharma (new zealand) limited - cefuroxime sodium 789mg equivalent to cefuroxime 750 mg;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to cefuroxime 750 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include:

Cefuroxime New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime

devatis limited - cefuroxime sodium 789mg equivalent to to cefuroxime 750mg - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to to cefuroxime 750mg - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria.

CEFUROXIME SODIUM injection, powder, for solution United States - English - NLM (National Library of Medicine)

cefuroxime sodium injection, powder, for solution

sagent pharmaceuticals - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase- producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - men

Cefuroxime for Injection New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime for injection

viatris limited - cefuroxime sodium 263mg equivalent 250 mg cefuroxime - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent 250 mg cefuroxime

Cefuroxime Multichem New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime multichem

multichem nz limited - cefuroxime sodium 802mg equivalent to cefuroxime 750 mg;   - powder for injection - 750 mg - active: cefuroxime sodium 802mg equivalent to cefuroxime 750 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1). indications include - respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septi

Cefuroxime Actavis New Zealand - English - Medsafe (Medicines Safety Authority)

cefuroxime actavis

teva pharma (new zealand) limited - cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg;   - powder for injection - 1.5 g - active: cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include: